ADC Shows Survival Benefit in Mets Cervical Cancer

The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.
MDedge News

source https://www.medscape.com/s/viewarticle/998004?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost